Smartphone lying beside a blue stethoscope on a white desk, illustrating the rules for advertising telemedicine and telehealth services in Singapore.
Home » Blog » Telemedicine Advertising in Singapore: What Telehealth Platforms and Clinics Can Promote

Telemedicine Advertising in Singapore: What Telehealth Platforms and Clinics Can Promote

Marketing a telehealth app or online consult in Singapore? The HCSA licence rule, MOH's MC and consult-time limits, HSA's drug-ad line, quizzes and Google/Meta policy.

Last updated 15 November 2026 — by Adrian Tan, SDM. Marketing guidance, not legal or medical advice. References are to MOH, HSA and SMC guidance and to Google and Meta policy pages read on 15 November 2026. Where we interpret how a rule applies, we say so.

A telehealth start-up wants to launch in Singapore with a campaign that would look normal almost anywhere else: “See a doctor in 5 minutes”, “Get your MC without leaving bed”, a $10-off first consult, a weight-loss landing page with a “Check if you’re eligible” quiz, and a dozen micro-influencers filming their unboxing of a cold-chain delivery. The founders have budgeted for Meta and TikTok, and plan to “add Google later”.

Almost every line of that plan breaks a Singapore rule. Several of those rules were written specifically for telemedicine in 2024, after regulators watched one-minute video consults and weight-loss jab promotions spread across social media. A telehealth brand that imports its playbook from the US, UK or Australia, where direct-to-consumer telehealth advertising is far looser, will find its ads pulled and its licence in question.

This guide is for telehealth platforms, clinics adding video consultations, men’s and women’s health brands, weight-management services and the agencies that market them. It covers who may advertise, what the copy may say, where the line falls between promoting a consultation and promoting a drug, how to build a compliant funnel, and what Google and Meta actually allow in Singapore.

The short version

  • Only a licensee, or someone it authorises, may advertise. A platform operator that promotes doctors’ teleconsultations without the licensee’s authorisation commits an offence under the Healthcare Services Act.
  • No MC promises and no “consult in X minutes”. MOH added both points to its advertising FAQs in November 2024.
  • No discounts, “free”, “from $X” pricing or giveaways. Only the exact final price may be published.
  • You may advertise a consultation for a condition, never a prescription medicine. That includes coded names, masked pen images and any GLP-1 weight-loss reference tied to an offer.
  • No quizzes or “Add to cart” flows that let a patient pick a prescription drug before seeing a doctor, even behind a login.
  • Google allows HCSA-licensed telemedicine providers to promote prescription services with certification; Meta does not accept Singapore prescription-drug ads at all.

Who is allowed to advertise a telemedicine service

Since Phase 2 of the Healthcare Services Act 2020 (HCSA) began on 26 June 2023, teleconsultation is no longer a grey area. A doctor or organisation providing consultations remotely needs an Outpatient Medical Service (or Outpatient Dental Service) licence with approval for the “remote provision” mode of service delivery. The old voluntary listing for telemedicine providers ended.

For marketers, the more important provision is section 31(1) of the HCSA. Only the licensee, or a person the licensee has authorised, may advertise a licensable healthcare service. MOH’s FAQs on the advertising rules name telemedicine platform operators specifically: an operator that advertises the services of licensed doctors without their authorisation breaches section 31(1). The penalty is a fine of up to $20,000, up to 12 months’ jail, or both, plus up to $1,000 a day for a continuing offence.

So if you are a marketplace or app that lists third-party clinics, you need written authorisation from each licensee before you run ads featuring their services. The licensee also stays responsible for ads placed by anyone it authorises, including its agency and, in our reading, an influencer it pays. “The agency wrote it” is not a defence for the clinic, and “the clinic approved it” does not move liability off the agency.

Which rules apply to whom

Party Main rules Regulator
Licensed clinic or telehealth provider HCSA and Healthcare Services (Advertisement) Regulations 2021; remote-provision licence conditions; Health Products Act ad rules MOH; HSA
Platform operator, marketplace or app HCSA s 31(1) authorisation; HSA guidance treats “indirect” providers such as software and directory platforms as in scope MOH; HSA
Individual doctor (including one appearing in ads) SMC Ethical Code and Ethical Guidelines (ECEG), including Section G on advertising and the telemedicine guidance in SMC Circular 2/2018 SMC
Agency and influencers Liable alongside the advertiser under the Health Products Act for co-produced drug content; licensee responsible for authorised ads HSA; MOH

One gap is worth knowing. The Singapore Medical Council has said it has no jurisdiction over advertisements placed by telemedicine providers as companies. Its rules bind individual doctors, so a doctor who endorses or fronts a non-compliant ad can face SMC proceedings even when the company itself is dealt with by MOH.

The advertising regulations, applied to telehealth

The Healthcare Services (Advertisement) Regulations 2021 apply to any advertisement with a “Singapore link”, meaning a person physically in Singapore can see it (regulation 3). That catches an overseas-hosted landing page and a regional Meta campaign that does not exclude Singapore. MOH does not pre-vet advertisements, so compliance is a judgement you make before you publish. Our aesthetic clinic advertising rules guide walks through the general regime in detail; here we focus on the points that bite hardest on telehealth.

Accuracy, and the two telehealth questions MOH added

Regulation 5(1)(a) requires claims to be factually accurate and capable of substantiation. In version 1.1 of its FAQs, updated on 22 November 2024, MOH added two questions that read as if they were written for telemedicine marketing:

  • Medical certificates. Mentioning or hinting at MCs in an advertisement, including through acronyms or graphics, is treated as soliciting or encouraging the use of the service. “Get your MC online” is out. So is a sick-day emoji next to a “Consult now” button.
  • Consultation length. Teleconsultation providers must not say or imply that a consult can be completed within a specified duration where that would be inaccurate or misleading. The FAQ’s reasoning is that the consult must be long enough for a proper clinical evaluation. “Done in 3 minutes” is a claim about clinical quality, not convenience.

No comparisons, even unnamed ones

Regulation 5(1)(c) bars comparing the quality of your service with another licensee’s and disparaging another licensee’s service, even where the competitor is not named. MOH’s own example in the FAQs is an advertisement implying “we don’t do one-second consults”, which readers would connect to the news reports about one telehealth provider. A telehealth brand trying to position itself as the “responsible” alternative has to do so by describing its own process factually, not by contrast.

Prices, promotions and “free”

Regulation 5(1)(g) prohibits content that solicits or encourages use of the service. MOH’s FAQs list what that covers in practice:

  • discounts, “free”, “interest-free” or “preferential rate” offers;
  • showing a usual price against a promotional price;
  • instalment amounts without the total price;
  • group-buying listings, giveaways and lucky draws;
  • redeeming airline miles or loyalty points.

Only the exact final price may be listed, with no “from” or “only” in front of it. Instalment plans and packages may be shown only at the point of payment. Regulation 15 adds that referral programmes and promotional packages may exist but may not be advertised, and MOH treats a patient’s screenshot of a referral offer as offending material. Laudatory statements, such as “Singapore’s most trusted telehealth app”, are banned even when you could prove them.

Where you may advertise, and push messaging

Regulation 6(1) permits advertising in newspapers, directories, journals, magazines, brochures and on the internet, including apps, websites and social media. Online shopping platforms are allowed. Regulation 6(4) is the one that catches app growth teams: no push messaging (SMS, WhatsApp, Messenger and similar) and no unsolicited physical mailers without the person’s prior written consent. A re-engagement push campaign to dormant app users needs that consent captured first, separately from PDPA consent. MOH’s FAQs also say paid search marketing is covered by the regulations, while organic SEO is not advertising unless it uses patient reviews or ratings.

Telehealth ad lines: what to write insteadBased on MOH FAQs on the HCS (Advertisement) Regulations v1.1 and HSA guidance v2 (Nov 2024)AvoidUse instead“See a doctor in 5 minutes”“Video consults with licensed doctors, 8am to 10pm”“Get your MC online”Remove: no MC references at all“First consult $10 off”“Consultation fee: $[exact amount]”“Lose weight with GLP-1 jabs”“Weight management consultations”“Check if you’re eligible for [drug]”“Book a consultation about [condition]”“We don’t do one-minute consults”Describe your own process, factuallyRed = phrasing MOH or HSA guidance treats as soliciting, misleading or advertising a prescription medicine
Most non-compliant telehealth copy fails on one of three points: speed of medical judgement, price inducements, or naming the medicine instead of the condition. Sources: MOH FAQs on the HCS (Advertisement) Regulations v1.1; HSA guidance for HCSA licensees and telemedicine providers v2.

The drug line: sell the consultation, never the medicine

This is where most telehealth campaigns in Singapore have run into trouble, and it comes from a different statute. Under the Health Products Act 2007 and the Health Products (Advertisement of Specified Health Products) Regulations 2016, prescription-only medicines may not be advertised to the public at all. Our guide to health product advertising rules covers that regime for product sellers. What changed in 2024 is that HSA published guidance aimed squarely at HCSA licensees and telemedicine providers, now in its second version dated 7 November 2024, with an FAQ document alongside it.

What HSA’s telemedicine guidance says

  • Scope. It covers “direct” providers that give care and “indirect” ones such as software, directory or payment platforms. Media treated as advertising include websites, Facebook, Instagram, TikTok, telemedicine apps and email newsletters. Hashtags of product names and images count.
  • Prescription-only medicines must not be advertised. Educational content may refer only to a therapeutic class, active ingredient or generic terms, and must not use brand names, product images, comparisons, prices or calls to action such as “get it now”.
  • No coded references. The FAQ gives examples of the workarounds it has seen: “Viagr@”, “S*xenda”, abbreviations like “RJN”, and images of injection pens with the label masked. All are treated as advertising the medicine.
  • The GLP-1 class rule. Because every GLP-1 receptor agonist is prescription-only, linking GLP-1s to an offer of sale is prohibited even without a brand name. “GLP-1 weight-loss programme, $X a month” advertises a prescription medicine.
  • No brand names in any form. Wegovy, Ozempic, Saxenda, Botox and Profhilo are out. Class terms such as “PDE-5 inhibitors” or “botulinum toxins” are acceptable in genuinely educational content.
  • No comparisons and no “HSA approved”. Brand-comparison tables, “works faster” and “lasts longer” claims are prohibited, and so is citing HSA approval as a selling point.
  • Shared liability. Material co-produced with a pharmaceutical company makes both parties liable.

MOH and HSA reinforced the point in a joint statement on 14 November 2024, reported by The Straits Times, saying prescription-only medicine advertisements may not be conveyed in any form of media, including telehealth platforms, and that discounts and instalment plans for them cannot be shown. A joint circular followed on 22 November 2024.

Regulators were already watching. In a parliamentary reply on 10 September 2024, MOH said HSA had investigated 16 cases of unauthorised sale or illegal advertising of GLP-1 drugs since 2022 and removed 82 online listings. On 25 September 2026, HSA warned again that GLP-1 drugs are increasingly promoted on social media as quick fixes, and that unapproved peptides were being sold under “research use only” labels.

Funnels, quizzes and “Check eligibility”: building a compliant journey

The part of HSA’s FAQs that most changes how telehealth funnels are built concerns the journey before the consultation. The FAQ says patients must not be able to select a prescription-only medicine before a consultation. “Buy now”, “Add to cart”, “Check eligibility”, “Start consultation”, an online quiz or a survey tied to a chosen drug is not allowed. A provider may offer a consultation for a condition, not for a drug. The FAQ adds that this applies behind a login too, so moving the drug menu into the logged-in app does not cure it.

In Singapore the condition comes first and the doctor decides on treatment. A compliant journey looks like this:

  1. Ad: names the condition or service area (“weight management”, “hair loss consultations”, “sexual health clinic online”) and the provider. No drug, no price inducement, no outcome promise.
  2. Landing page: explains who the service is for, how the video consultation works, the doctors’ names and qualifications, the exact consultation fee, and what happens if the doctor decides medication is not appropriate.
  3. Intake: a medical history form about the condition, not a product selector. It feeds the doctor’s assessment and does not output a recommended drug.
  4. Consultation: real-time, two-way audio-visual contact. MOH’s position, reported by The Straits Times in November 2024, is that doctors and patients must see and hear each other.
  5. Post-consult: treatment options, including medicine names and prices, are discussed privately with the patient who has been assessed. This is clinical communication, not public advertising.

What the licence conditions add

MOH’s licence conditions for remote provision of outpatient medical services sit behind the advertising rules and shape what you can truthfully promise. The version we read (marked as a draft on MOH’s site; MOH Circular 64/2025 set 17 October 2025 as the date modified conditions took effect) requires an appropriate and adequate clinical assessment before prescribing or issuing an MC, says text-only, self-service questionnaires without two-way communication are not enough, and requires escalation where a patient receives repeated MCs. SMC Circular 2/2018 says doctors practising telemedicine must provide care equivalent to in-person care and must explain the limitations of telemedicine before the patient consents. Any ad that implies a guaranteed prescription or certificate contradicts those duties.

The enforcement case everyone in the sector knows

On 16 August 2024, MOH instructed MaNaDr Clinic to stop providing teleconsultations. MOH said that in a sampled month, more than 100,000 video consultations had lasted one minute or less, the shortest lasting one second, and that over 1,500 patients had received five or more MCs. MOH later revoked the clinic’s outpatient medical service licence with effect from 20 December 2024, citing an entrenched culture of disregard for ethical and clinical standards. That case is the background to the MC and consultation-time questions in MOH’s advertising FAQs, and it explains why regulators read speed-and-MC marketing as a red flag rather than a feature.

How Singapore’s telehealth ad rules built upSources: SMC, MOH, HSAApr 2018SMC Circular2/2018Jan 2022HCS Ad Regsin forceJun 2023HCSA Phase 2:remote provisionAug 2024One-minuteconsults case7 Nov 2024HSA guidance v2+ FAQs22 Nov 2024MOH FAQs: MCs,consult durationOct 2025Licence conditionsmodifiedMost of the telehealth-specific advertising guidance was issued within three months of the August 2024 case.
The telehealth-specific advertising rules arrived in a cluster in late 2024. Campaigns planned from pre-2024 playbooks are the ones most likely to fail. Sources: SMC Circular 2/2018; MOH press releases and FAQs; HSA guidance v2.

Influencers, reviews and doctors on social media

Influencer marketing is where telehealth brands most often assume the rules are softer, and in Singapore they are stricter. Regulation 14 of the advertising regulations prohibits licensees from using testimonials, endorsements or patient photographs in their advertising, and MOH’s FAQs say paid reviews are banned even if the sponsorship is disclosed. An influencer filming their own consultation and weight-loss journey, paid or gifted by you, is a testimonial in an advertisement. Disclosure labels such as “#ad” make it transparent; they do not make it lawful.

What remains possible:

  • Organic reviews that patients post on third-party sites, unpaid and unsolicited, are not treated as your advertising. You may not reproduce them on your own website or social accounts, and you should not incentivise them.
  • Interviews with media or vloggers are allowed under regulation 9 only if your clinic did not solicit them. A “collaboration” you pitched and paid for is not an unsolicited interview.
  • Educational creator content about a condition, without your service as the call to action, testimonials or drug references, is the safest form of creator work.
  • Your own doctors may produce educational content, but SMC’s ECEG Section G applies to them personally: information must be factual and verifiable, not exploit patients’ fears, and not be sensational. A doctor who appears in an ad naming a prescription medicine is exposed under both HSA rules and the SMC code.

Our guide to social media for clinics covers content formats that work within these limits, and the pharmacy advertising rules guide covers the medicine-delivery side of a telehealth service.

Google, Meta and the platforms

The two biggest ad platforms treat Singapore telehealth very differently, and the difference should shape your channel mix before you write any copy.

Platform Telehealth / prescription services in Singapore What it means
Google Ads Telemedicine “allowed with limitations”: providers licensed under the HCSA may promote prescription drug services, with Google certification required Apply for certification before launch; Singapore law still bars naming prescription medicines in the ad
Meta (Facebook, Instagram) Prescription drug ads accepted only in the US, Canada and New Zealand; Singapore not eligible. General telehealth ads and educational ads need no authorisation; no targeting under 18 Promote the service and conditions, never prescription treatment
Google remarketing Health is a sensitive interest category for personalised advertising Do not build remarketing lists from condition-specific pages

Google’s certification route is useful, but it is not a licence to name drugs. In practice, a Singapore telehealth search campaign bids on condition and service queries, and its ad copy reads exactly like the compliant landing page above. Our guide to Google Ads for clinics in Singapore covers keyword strategy and certification in more depth.

Data handling deserves a word too. PDPC’s advisory guidelines for the healthcare sector say that using a patient’s personal data to market unrelated health products is unlikely to fall within deemed consent, and regulation 6(4) separately requires prior written consent for push messaging. Pixels firing on condition-specific pages also send health-related signals to ad platforms; see our guide to PDPA-compliant marketing tracking before you instrument a telehealth funnel.

A pre-launch checklist for telehealth campaigns

  1. Confirm the provider holds an OMS or ODS licence with remote-provision approval, and that every clinic advertised by a platform has given written authorisation.
  2. Strip every reference to MCs, consultation duration and speed of approval.
  3. Replace any discount, “free”, “from” price or instalment figure with the exact final fee; move packages to the payment step.
  4. Remove drug names, coded names, masked pens, GLP-1 references tied to an offer, and “HSA approved” claims.
  5. Check the funnel: no drug selection, quiz, “Check eligibility” or cart before a consultation, in the app or on the web.
  6. Remove testimonials, patient photos and paid reviews from ads, website and social accounts; brief creators on educational-only content.
  7. Capture prior written consent before any SMS, WhatsApp or push campaign.
  8. Apply for Google healthcare certification; keep Meta copy to service-level messaging.
  9. Keep a dated file of each ad, its approver and the evidence for every factual claim.

The bottom line

Telemedicine is one of the few areas where Singapore wrote new advertising guidance in response to how the market was actually behaving. The result is a clear set of lines: advertise the consultation, never the medicine; describe your process, never the speed of a medical decision; publish your fee, never a promotion; and keep patients’ and influencers’ stories out of your ads. Inside those lines, there is still plenty of room for good marketing, built on condition-focused search, clear explanation and credible doctors.

If you are launching or scaling a telehealth service and want campaigns that comply and still perform, our performance marketing team in Singapore can help, and you can see the results we have delivered in our client case studies. For the wider picture, read our complete guide to performance marketing in Singapore, our overview of digital marketing for healthcare in Singapore, and our guide to fertility clinic and IVF advertising.

Frequently asked questions

Can a telehealth platform advertise weight-loss injections like Wegovy or Ozempic in Singapore?

No. They are prescription-only medicines, which may not be advertised to the public. HSA’s guidance also says linking GLP-1 drugs to an offer of sale is prohibited even without a brand name. You may advertise weight-management consultations, with treatment decided by the doctor.

Is a “Check your eligibility” quiz allowed on a telemedicine landing page?

Not if it is tied to a prescription medicine. HSA’s FAQs say patients must not be able to select a prescription-only medicine before a consultation, including through quizzes, surveys, “Check eligibility” or “Add to cart”, and that this applies behind a login too. A medical history form about a condition is fine.

Can we advertise a first-consult discount or instalment plan?

No. MOH treats discounts, “free” offers, usual-versus-promotional prices and instalment amounts as soliciting the use of a healthcare service. Publish the exact final fee with no “from” prefix, and show packages or instalment plans only at the point of payment.

Can we say a teleconsultation takes 5 minutes, or that patients get an MC?

No. MOH’s November 2024 FAQs say teleconsultation ads must not imply a consult can be completed within a specified duration where that would be misleading, and that mentioning or hinting at MCs, including through acronyms or graphics, is not allowed.

Can influencers review our telehealth service?

Not as part of your advertising. Licensees may not use testimonials or endorsements, and MOH says paid reviews are banned even when disclosed. Unpaid, unsolicited reviews on third-party sites are not your advertising, but you may not reproduce them on your own channels.

Do Google and Meta allow Singapore telemedicine ads?

Google allows HCSA-licensed telemedicine providers to promote prescription drug services once certified, although Singapore law still bars naming the drugs. Meta accepts prescription drug ads only in the US, Canada and New Zealand, so in Singapore you can promote telehealth services generally but not prescription treatment.



Want to know where you actually rank?

We will run a free visibility check across your target searches and send back an honest read — no obligation.

Picture of Adrian Tan

Adrian Tan

A seasoned digital marketing professional with over 15 years of experience, I have built and executed high-impact digital strategies across SEO, SEM, Social Media Marketing (SMM), Social Media Advertising (SMA), content marketing, performance marketing, and integrated digital campaigns. My expertise extends beyond individual channels, focusing on how every aspect of digital marketing works together to drive measurable business growth. Throughout my career, I have successfully managed and optimized campaigns across a wide range of industries, including technology, finance, healthcare, retail, e-commerce, education, real estate, hospitality, and professional services. This cross-industry experience has enabled me to develop data-driven strategies tailored to unique business objectives, customer behaviors, and competitive landscapes. I have partnered with multinational corporations (MNCs) as well as established enterprises and high-growth businesses, helping them strengthen their digital presence, increase brand visibility, generate qualified leads, improve customer acquisition, and maximize return on marketing investment. From developing comprehensive digital strategies to managing multi-channel campaigns with substantial budgets, I have consistently delivered results through continuous optimization, analytics, and innovation. My expertise includes technical and on-page SEO, enterprise SEO strategies, paid search (Google Ads, Microsoft Ads), paid social campaigns across Meta, LinkedIn, TikTok, and other platforms, marketing automation, conversion rate optimization (CRO), web analytics, audience segmentation, content strategy, and performance reporting. I combine analytical thinking with creative problem-solving to ensure every campaign aligns with broader business goals. What sets me apart is my holistic understanding of the digital marketing ecosystem. Rather than viewing SEO, paid media, social media, and content as isolated disciplines, I develop integrated strategies where every channel supports the customer journey—from awareness and engagement to conversion, retention, and advocacy. This full-funnel approach allows businesses to achieve sustainable growth while adapting to evolving market trends and consumer expectations. Driven by continuous learning and innovation, I stay at the forefront of emerging technologies, AI-powered marketing, automation, and evolving digital platforms. My passion lies in transforming complex marketing challenges into scalable, measurable, and sustainable growth opportunities that deliver long-term business success.

On this page

Share

Get found by customers already looking for you

A free, honest look at where you stand today and what it would take to move.

Not sure where you stand?

Tell us about your business and we will take an honest look at where you are today — and what it would take to get where you want to be.

No obligation · a human replies within one working day